Cargando…
Patients with relapsed/refractory hairy‐cell leukemia
BACKGROUND: Hairy cell leukemia (HCL) is a rare chronic B‐cell neoplasm with good long‐term prognosis. First and second‐line therapies include purine nucleoside analogues (PNAs) and rituximab, but until recently, limited alternative options were available for patients with two or more relapses. AIM:...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955050/ https://www.ncbi.nlm.nih.gov/pubmed/34250762 http://dx.doi.org/10.1002/cnr2.1495 |